Race Oncology Ltd (ASX: RAC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Race Oncology Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $326.85 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 159.52 million
Earnings per share -0.065
Dividend per share N/A
Year To Date Return -42.22%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Race Oncology Ltd (ASX: RAC)
Latest News

Earnings Results

Race Oncology share price leaps 5% on quarter of ‘major advances’

Quarter dominated by promising results have investors revved up...

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Up 38% in a month, what’s sparking the recent Race Oncology share price run-up?

What a month it has been for Race Oncology shareholders.

Read more »

A man in a wheelchair stretches both arms into the air in success.
Index investing

ASX 200 healthcare shares provided some pain relief today. Here’s why

The healthcare sector ended Thursday as the best performer on the ASX.

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Boy in business suit smiles with arms crossed and rockets attached to his back representing the rocketing BrainChip share price
Healthcare Shares

Why did the Race Oncology share price rocket 10% today?

Investors view Race Oncology's latest release in a positive light.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Race Oncology share price soars 16% on buyback news

The pharmaceutical company's shares are receiving a welcome boost today.

Read more »

Female doctor with a mask holds out hand in a stop gesture.
Healthcare Shares

Why is the Race Oncology share price in a trading halt?

Race Oncology is set to release some trial results to the market in the coming days.

Read more »

a woman looks distressed as she stares dramatically at her phone watching the Megaport share price crashing today
Share Market News

5 ASX shares making unbelievable news this week

These five ASX shares made headlines this week.

Read more »

RAC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Race Oncology Ltd

Race Oncology Ltd is an Australian pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field.

RAC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
08 Aug 2022 $2.08 $0.06 2.97% 75,027 $2.04 $2.13 $2.03
05 Aug 2022 $2.02 $0.00 0.00% 216,286 $2.05 $2.17 $2.02
04 Aug 2022 $2.02 $-0.05 -2.42% 68,255 $2.06 $2.09 $2.02
03 Aug 2022 $2.07 $0.00 0.00% 101,240 $2.09 $2.12 $2.02
02 Aug 2022 $2.07 $-0.08 -3.72% 74,396 $2.15 $2.15 $2.07
01 Aug 2022 $2.15 $0.00 0.00% 45,568 $2.13 $2.18 $2.12
29 Jul 2022 $2.15 $0.01 0.47% 57,735 $2.14 $2.22 $2.11
28 Jul 2022 $2.14 $0.04 1.90% 23,343 $2.12 $2.15 $2.09
27 Jul 2022 $2.10 $-0.07 -3.23% 105,977 $2.17 $2.17 $2.10
26 Jul 2022 $2.17 $-0.06 -2.69% 51,157 $2.24 $2.24 $2.14
25 Jul 2022 $2.23 $0.08 3.72% 120,176 $2.18 $2.28 $2.18
22 Jul 2022 $2.15 $0.11 5.39% 76,708 $2.07 $2.20 $2.04
21 Jul 2022 $2.04 $-0.07 -3.32% 174,960 $2.12 $2.20 $2.02
20 Jul 2022 $2.11 $0.01 0.48% 18,969 $2.10 $2.17 $2.10
19 Jul 2022 $2.10 $-0.03 -1.41% 41,499 $2.15 $2.18 $2.07
18 Jul 2022 $2.13 $-0.09 -4.05% 211,082 $2.22 $2.22 $2.05
15 Jul 2022 $2.22 $-0.05 -2.20% 23,337 $2.27 $2.27 $2.22
14 Jul 2022 $2.27 $0.05 2.25% 93,816 $2.25 $2.28 $2.17
13 Jul 2022 $2.22 $-0.01 -0.45% 19,385 $2.23 $2.27 $2.22
12 Jul 2022 $2.23 $-0.16 -6.69% 55,574 $2.37 $2.39 $2.21

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
16 May 2022 John Cullity Expiry 189 $357,007
Options expired.
16 May 2022 Daniel Tillett Expiry 672 $1,267,662
Options expired.
16 May 2022 Phillip(Phil) Lynch Expiry 20 $39,505
Options expired.
16 May 2022 Mary Harney Expiry 400 $754
Options expired.
04 Mar 2022 Daniel Tillett Buy 20 $55,763
On-market trade.
10 Jan 2022 John Cullity Sell 300 $995,174
On-market trade.
21 Dec 2021 Daniel Tillett Issued 10 $30,000
Participation in share purchase plan.
21 Dec 2021 Mary Harney Issued 10 $30,000
Participation in share purchase plan.
21 Dec 2021 Phillip(Phil) Lynch Issued 10 $30,000
Participation in share purchase plan.
14 Dec 2021 Daniel Tillett Buy 2 $7,732
On-market trade.
10 Dec 2021 Daniel Tillett Buy 17 $59,188
On-market trade.
12 Nov 2021 John Cullity Exercise 3 $710,000
Exercise of options.
12 Nov 2021 John Cullity Buy 3 $710,000
Exercise of options.
04 Nov 2021 John Cullity Sell 217 $709,999
On-market trade.
02 Sep 2021 John Cullity Sell 61 $192,798
On-market trade.
23 Aug 2021 John Cullity Exercise 1 $187,499
Exercise of options.
23 Aug 2021 John Cullity Buy 1 $187,499
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr John Cullity Executive ChairmanExecutive Director Apr 2018
Dr Cullity is Managing Director at BioSynergy Partners, a New York and Melbourne based advisory recently spun out of Torreya - the renowned life sciences investment bank. He additionally serves on the Boards of several life sciences companies including Ceramedix (seeded by Torreya). At Torreya, he provided strategic advisory on Mergers and Acquisitions, Partnering and Financing to life-science companies worldwide. Prior to joining Torreya, he was a senior member of the Business Development team at Sanofi Pharmaceuticals, where he led buy side transactions in oncology and diabetes. Earlier in his career, Dr Cullity was Head of Strategic Pricing and Reimbursement at Sanofi, Director of Health Economics at Schering-Plough, and Consultant at A.T. Kearney. He has also worked at the World Bank and the World Health Organisation.
Dr Daniel Tillett Chief Scientific OfficerExecutive Director Sep 2019
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company in the genomics space. He was previously a Senior Lecturer within the School of Pharmacy at La Trobe University where he lectured on biochemistry, biotechnology, pharmacy, microbiology and virology. Dr Tillett's Ph.D on the molecular genetics and biochemistry of microcystin toxin production was awarded by the University of New South Wales in 2000.
Mr Phillip(Phil) R Lynch Chief Executive OfficerManaging Director Jun 2020
Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an executive and board director, with a diverse background across corporate development, strategy, financial performance, marketing and governance. In his former role as Vice President of Commercial Growth and Innovation at Johnson & Johnson Asia Pacific (J&J AP), 2016 - 2019), Mr Lynch partnered with the Mergers and Acquisitions team to drive the integration and growth of acquired businesses. He retired from J&J AP in December 2019 following the >$2b acquisition and integration of a significant Japanese business. Mr Lynch was previously the Managing Director and CEO of J&J Pacific (AU/NZ - 2009 to 2015). He had further leadership roles across the Asia Pacific region, including Managing Director of various J&J divisions in Thailand, Vietnam, and Singapore. He is currently the Chair of Consumer Health Products Australia.
Ms Mary Harney Non-Executive Director Feb 2021
Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. Ms Harney was formerly the CEO of Royal Australasian College of Surgeons; CEO of Gardiner Research Foundation; COO and Director of Office of Cancer Research for Peter MacCallum Hospital, and; COO of Cerylid Biosciences. Other former roles were with CSL, Amrad, BIOPROPERTIES and Royal Melbourne Hospital.
Mr Peter Webse Company Secretary Aug 2016
-
Peter Webse Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Dr Daniel Tillett 13,450,000 9.31%
Dr William James Garner 8,979,939 6.22%
Mr Phillip Richard Perry 5,715,694 3.96%
Biosynergy Partners Pty Ltd 3,787,878 2.62%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,452,236 1.70%
Mr Mark Phillip Juan 2,301,316 1.59%
Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,600,000 1.11%
Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,490,000 1.03%
Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C> 1,200,000 0.83%
Citicorp Nominees Pty Limited 1,140,603 0.79%
Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,125,000 0.78%
Mr Sandor Helby 1,018,000 0.71%
Mr Andrew Jacobs 970,223 0.67%
Mr Brian James Walker 707,290 0.49%
Mr Graeme Stewart Pocknall & Mrs Vivienne Glynis Pocknall 617,830 0.43%
T&G Corporation Pty Ltd 589,400 0.41%
Mr Simon Rogers <Rogers Family A/C> 577,167 0.40%
Ditthavong & Steiner PC 538,478 0.37%
Beppe Super Pty Limited <Pake Superannuation Fund A/C> 532,000 0.37%
The Trust Company (Australia) Limited <MOF A/C> 6 4.30%

Profile

since

Note